Eli Lilly sues Empower, Strive over tirzepatide products
Eli Lilly has sued two large compounding pharmacies, alleging they deceive patients and put them at risk with compounded versions of the obesity drug tirzepatide in combinations or forms that haven’t...
View Article‘It’ll be a challenge’: BIO chief Crowley addresses seismic FDA overhaul
WASHINGTON — The size and scope of the FDA that began Tuesday won’t be the same as the day nears a brutal conclusion for agency staffers that were laid off or forced to resign. Sitting in ...
View ArticleJudge orders HHS, other agencies to 'undo' probationary worker firings
The HHS and other federal agencies must reverse the terminations of probationary government workers that were fired in the states challenging the cuts, under a new order issued late Tuesday by a...
View ArticleNew CDMO emerges, acquires cell and gene manufacturer Landmark Bio
New CDMO Artis BioSolutions has come out of stealth and is snapping up cell and gene therapy manufacturer Landmark Bio for an undisclosed amount. The new San Diego-headquartered manufacturer, which is...
View ArticleArie Belldegrun nabs two leaders for Vida Ventures amid plans for fourth fund
Arie Belldegrun's life sciences venture firm secured a pair of new managing directors after parting ways with two leaders last fall. Vida Ventures said Wednesday that it hired Matthew Cohen, most...
View ArticleEdgewise's heart drug shows promise in Phase 2 trial
Edgewise Therapeutics’ cardiac sarcomere modulator has passed a mid-stage test in patients with a genetic heart muscle disease. The biotech’s EDG-7500 produced “meaningful” reductions in left...
View ArticleAtsena raises $150M to target rare form of blindness with gene therapy
There's still money to be raised by gene therapy startups with good clinical data. On Wednesday, North Carolina biotech Atsena Therapeutics said it had raised a $150 million Series C to try and be the ...
View ArticleExclusive: Former Pfizer CSO Mikael Dolsten to advise AI unicorn Formation Bio
Can AI make an avatar of Mikael Dolsten? The former chief scientific officer of Pfizer will try to find out now that he's starting a new chapter at Formation Bio after nearly 16 years at ...
View ArticleSanofi licenses autoimmune asset from Nurix; Sumitomo Pharma’s changes
Plus, news about Gilead, Roche, Desentum, Inhibrx and Pila Pharma: After 2020 deal, Sanofi licenses Nurix’s autoimmune disease asset: The discovery-stage program targets a “previously undruggable”...
View ArticleTang Capital's Concentra nabs a win, making a deal to buy Allakos
Tang Capital's shell company Concentra Biosciences secured its first major deal since late 2023. Allakos has agreed to be acquired by Concentra for $0.33 per share in cash, and the California biotech...
View ArticleBIO CEO on tariffs, MAHA and the future of the biotech industry
John Crowley is clear-eyed about the obstacles he faces. As CEO of the trade group BIO, he’s been tasked with mounting a political comeback for an industry that has taken its punches from Democrats and...
View ArticleEli Lilly adds obesity startup knownwell to its direct-to-consumer service
Eli Lilly’s direct-to-consumer service has added another telehealth startup to its line-up of providers who can prescribe its medications, as it prepares to see more demand for obesity drugs following...
View ArticleNew FDA Commissioner Marty Makary addresses staff a day after firings
New FDA Commissioner Marty Makary took to the stage at the regulator's Maryland headquarters on Wednesday, in his first public communication to much of the agency since Tuesday's mass firings....
View ArticleFTC's fight against PBMs is paused
The FTC’s legal fight against three major pharmacy benefit managers is on hold after two agency commissioners have been removed by the Trump Administration. The commissioners, Rebecca Slaughter and...
View ArticleBiopharma execs rethink Trump impact after FDA cuts
This week’s sweeping layoffs at the FDA have caused some biopharma leaders to change their tune on the Trump administration. After President Donald Trump’s victory in November, many biopharma CEOs...
View ArticleTrump tariffs exempt pharma companies for now
Editor’s note: This is an updated and corrected version of a story that ran on April 2 after the administration’s announcement, which contained several (apparently conflicting) documents. We’ve...
View ArticleTrump's tariff rollout leaves many questions for drugmakers
A rapid cascade of seemingly conflicting details from President Donald Trump’s tariff announcement left large drugmakers on Wednesday trying to figure out the impact on the industry, with many...
View ArticleExclusive: Neurona bags $102M to treat epilepsy with cell therapy
A few cell and gene therapy biotechs are doing alright this week. The latest is Neurona Therapeutics, which exclusively told Endpoints News that it collected another $102 million in an upsized,...
View ArticleSarepta, Roche pause Elevidys trials in Europe following patient death
Sarepta and Roche are hitting the brakes on three trials of their Duchenne gene therapy Elevidys in response to a request by the European Medicines Agency. The drugmakers are pausing enrollment and...
View ArticleNovartis’ Chinook-originated kidney disease drug gets accelerated approval
One of Novartis’ most important clinical catalysts of the year came Thursday, with the accelerated approval in the US of its rare kidney disease drug. Atrasentan, which is now named Vanrafia, is a...
View ArticleDaymark Health raises $11.5M to care for cancer patients
Oncologist Justin Bekelman started Daymark Health to better support cancer patients outside the clinic. The startup launched on Thursday with a $11.5 million seed round co-led by Maverick Ventures and...
View ArticleMoonLake discloses up to $500M in financing; OSR’s deal with innovation fund
MoonLake Immunotherapeutics gets financing worth up to $500M: The company will get $75 million upfront from Hercules Capital. MoonLake, which went public in 2022, had about $448 million in cash before ...
View ArticleAnother TIGIT trial fails as BeiGene scraps Phase 3 drug
What was once a promising area of cancer immunotherapy has had another late-stage failure. BeiGene said Thursday that a Phase 3 study for its anti-TIGIT drug, called ociperlimab, was halted for ...
View ArticleAldeyra gets second CRL for dry eye disease drug
The FDA once again rejected Aldeyra's potential dry eye disease treatment, known as reproxalap, as the agency requested more trial data after the resubmitted drug approval request "failed to...
View Article